Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: A multivariate regression analysis of 163 untreated patients
- 1 December 1989
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 43 (S51) , 99-104
- https://doi.org/10.1111/j.1600-0609.1989.tb01500.x
Abstract
The presenting clinical features of 163 previously untreated patients with multiple myeloma were correlated with survival duration using univariate and multivariate regression analyses. The univariate proportional hazard analysis ranked the parameters in the following order of importance: platelet count, haemoglobin level (Hb), tumour cell mass stage, lytic bone lesions, creatinine and age. When the individual contribution of each variable was assessed by multivarite regression analysis, platelet count was confirmed to be the dominant feature for prognosis, while clinical stage provided additional information. The introduction of platelet count could then be used to improve the discriminating power of Durie & Salmon staging, by allowing separation of the high‐risk group (stages II and III) into a smaller subgroup (22%) of thrombocytopenic patients (< 150 × 109 platelets/l) whose risk of death was actually very high (median survival: 9 months) and a larger subgroup (46%) of patients with normal platelet count and intermediate or standard risk (median survival: 48 months).Keywords
This publication has 14 references indexed in Scilit:
- Prognostic variables and clinical staging in multiple myelomaBlood, 1989
- High-dose melphalan with autologous bone marrow transplantation for multiple myelomaBlood, 1986
- Staging systems for multiple myeloma: a comparisonBritish Journal of Haematology, 1985
- Staging and survival in multiple myelomaScandinavian Journal of Haematology, 1984
- Prognostic value of bone marrow plasma cell infiltration in stage I multiple myelomaBritish Journal of Haematology, 1983
- Critical Study of Staging in Multiple MyelomaScandinavian Journal of Haematology, 1983
- Prognostic features in the third MRC myelomatosis trial.British Journal of Cancer, 1980
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958